CompletedPhase 2NCT00892177
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Evanthia Galanis, MDMayo Clinic
- Intervention
- bevacizumab(biological)
- Enrollment
- 144 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2019
Study locations (30)
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- Palchak David MD, Pismo Beach, California, United States
- Aurora Presbyterian Hospital, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
- St. Anthony Central Hospital, Denver, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States
- St. Joseph Hospital, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- North Colorado Medical Center, Greeley, Colorado, United States
- Sky Ridge Medical Center, Lone Tree, Colorado, United States
- Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00892177 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland